Prosecution Insights
Last updated: November 20, 2026
Application No. 19/542,501

METHODS AND DEVICES FOR TREATING VASCULAR DISEASE

Final Rejection §103
Filed
Feb 17, 2026
Priority
May 04, 2022 — provisional 63/338,114 +2 more
Examiner
KNAUSS, CHRISTIAN D
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Route 92 Medical Inc.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
2y 6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
307 granted / 430 resolved
+1.4% vs TC avg
Strong +33% interview lift
Without
With
+32.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
33 currently pending
Career history
475
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
19.3%
-20.7% vs TC avg
§112
26.3%
-13.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 430 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Claims 1, 3-25, and 27-30 are pending in the application. Claims 2 and 26 have been canceled. Claims 1, 21, 23, 27, and 28 have been amended. Terminal Disclaimer The terminal disclaimer filed on 9/23/26 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of any patent granted on Application Number 18/311,797. has been reviewed and is accepted. The terminal disclaimer has been recorded. Information Disclosure Statement The information disclosure statement (IDS) submitted on 9/23/26 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3-5, 7, 16, and 21 are rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Jago (US 2020/0253579 A1) and Stenzel (US 2007/0010863 A1). Regarding claims 1, 5, and 7, Fischell discloses (Figures 23A-23F) a method of treating a vasculature (45), the method comprising: advancing a catheter system through a base sheath (44) towards a vessel having a blood vessel narrowing (52), the catheter system comprising: an inner catheter (54) having a non-expandable, flexible, distal end region (118) with a taper (paragraphs 0037, 0125), at least one radiopaque marker (310) to identify the taper (Figure 8A; paragraph 0195), a distal opening sized to receive a guidewire, and a flexible, distal end region to dilate a narrowing of a vessel; and an outer catheter (142) having a catheter lumen and a distal end; positioning the taper of the distal end region (118) of the inner catheter distal to the distal end of the outer catheter (Figure 23A); and crossing the blood vessel narrowing with the taper based on a position of the at least one radiopaque marker relative to the blood vessel narrowing to dilate the blood vessel narrowing (Figures 23B, 23C; paragraphs 0205-0207). Fischell fails to disclose that the inner catheter is a non-expandable, single-lumen inner catheter, wherein the single lumen extends to the distal opening of the inner catheter, the distal opening sized to receive a guidewire, and wherein the flexible, distal end region sized to dilate a narrowing of a vessel. Fischell also fails to disclose that the vessel is at least at a level of a carotid artery or a cerebral artery, wherein the blood vessel narrowing is a proximal atherosclerotic lesion in a proximal vessel that is a common carotid artery, an external carotid artery, or an internal carotid artery, and wherein crossing the blood vessel narrowing comprises advancing the catheter system through the proximal atherosclerotic lesion and advancing towards a distal blood vessel occlusion in a distal vessel. Fischell also fails to disclose that the distal end region is substantially unreinforced and fully polymeric. Fischell discloses that the inner catheter serves to pre-dilate a lesion with a pre-dilatation balloon (96; paragraph 0125). Jago teaches (Figure 2) that it is known in the art for a proximal atherosclerotic lesion (72) to be formed in a proximal vessel and a distal occlusion to form in a distal vessel (74). Jago teaches that the proximal vessel is a common carotid artery (10a) and the distal vessel is a distal carotid artery (10b). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the method disclosed by Fischell treat a blood vessel narrowing at the level of a carotid artery, wherein the blood vessel narrowing is a proximal atherosclerotic lesion in a proximal vessel that is a common carotid artery, and wherein crossing the blood vessel narrowing comprises advancing the catheter system through the proximal atherosclerotic lesion and advancing towards a distal blood vessel occlusion in a distal vessel, as Jago teaches it is known in the art for obstructions to form in the common carotid artery and the distal carotid artery. This modification would treat an occlusion that restricts flow of blood to the brain (Jago, paragraph 0013). In the same field of endeavor, Stenzel teaches (Figures 11-13) advancing a non-expandable, single lumen catheter (30; NOTE: Figure 11 depicts a balloon. However, Stenzel teaches the device may include an inflation balloon) with a flexible (paragraphs 0033 and 0035), distal tapered end region (20) over a guidewire (12) to a lesion (16). Stenzel teaches the guidewire (12) is positioned within the single lumen (38) of the inner catheter (Figure 11). Stenzel teaches the size and shape of the lesion (16) may block the vessel (14) to the extent that the guidewire is unable to cross the lesion (16). Stenzel teaches using the tapered end region (20) of inner catheter (30) to cross an occlusion (16) in the artery (Figures 12 and 13). Stenzel teaches (Figures 12 and 13) that the tapered end region (20) of the inner catheter (30) pre-dilates the occlusion (16) in the artery (14) as the catheter system is advanced (Stenzel, paragraph 0061). Stenzel teaches that the distal tapered end region is substantially unreinforced and fully polymeric (paragraphs 0033 and 0035). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to substitute the inner catheter having a non-expandable, single lumen configuration and a substantially unreinforced and fully polymeric distal end region, taught by Stenzel, for the inflatable inner catheter configuration taught by Fischell in view of Jago. Substitution of one known element (the pre-dilating catheter configuration taught by Stenzel) for another element (the expandable pre-dilating inner catheter configuration disclosed by Fischell) providing the same function to yield predictable results (pre-dilating occlusions to allow the catheter system to pass through occlusions where the size and shape of the occlusion may block the vessel) would have been obvious to one of ordinary skill in the art at the time of the invention. Regarding claim 3, Fischell as modified by Jago and Stenzel teaches that the blood vessel narrowing (52) is due to an atherosclerotic lesion (Fischell, paragraph 0145). Regarding claim 4, Fischell as modified by Jago and Stenzel teaches withdrawing the inner catheter from the catheter lumen (Fischell, Figure 23E); advancing a stent delivery system comprising a stent (200) through the catheter lumen; and deploying the stent of the stent delivery system against the atherosclerotic lesion (Fischell, Figure 23F; paragraph 0211). Regarding claim 16, Fischell as modified by Jago and Stenzel teaches (Stenzel Figure 11) inner catheter comprises a maximum outer diameter and the taper of the distal end region tapers from the maximum outer diameter to a second outer diameter at a distal-most end. Regarding claim 21, Fischell as modified by Jago and Stenzel teaches (Fischell, Figures 23A-23F) advancing the catheter system through the base sheath comprises advancing the catheter system over a guidewire (42) extending through the distal opening. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Jago (US 2020/0253579 A1) and Stenzel (US 2007/0010863 A1) as applied to claim 5 above, and further in view of Chermoni (US 2002/0156496 A1). Regarding claim 6, Fischell as modified by Jago and Chermoni teaches the invention substantially as claimed. However, the combined teaching fails to teach treating the distal blood vessel occlusion. In the same field of endeavor, Chermoni teaches that it is often necessary to treat multiple occlusions in a single procedure. For example, it may be necessary to insert a large diameter stent at one location, a small diameter stent at a second location and to perform a balloon angioplasty without a stent at a third location (paragraph 0003). Chermoni teaches (Figures 1-13) that a catheter system is inserted towards a distal occlusion, but first treats a first desired location, a first occlusion. After the first occlusion is treated, the catheter is navigated to the distal occlusion, and the distal occlusion is treated (paragraph 0044). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to first treat a proximal occlusion in a proximal vessel and then navigate the catheter system towards a distal occlusion in a distal vessel, and then treat the distal occlusion, as taught by Chermoni. This modification would allow multiple occlusions to be treated in the same procedure, without removing the catheter system from the body, which would cause much discomfort to the patient, prolong the duration of the procedure, and increase the chances of damaging a blood vessel (Chermoni, paragraph 0003). Claims 8, 9, 14, 15, 20, and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Jago (US 2020/0253579 A1) and Stenzel (US 2007/0010863 A1) as applied to claim 1 above, and further in view of Wilson et al. (US 2018/0193042 A1) (“Wilson”). Regarding claims 8 and 9, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. However, the combined teaching fails to teach the taper of the distal end region is 0.5 cm - 4.0 cm and the taper has a taper angle relative to a center line of the distal end region that is 0.9 - 1.6 degrees. Wilson teaches (Figures 2A and 2B) an inner catheter (300) comprising no more than one lumen (368; paragraph 0150) and having a non-expandable, flexible, distal end region (346) with a taper and at least one radiopaque marker (344a/344b) to identify the taper (paragraphs 0145, 0158), wherein the taper of the distal end region is 0.5 cm - 4.0 cm (paragraph 0166), and wherein the taper has a taper angle relative to a center line of the distal end region that is 0.9 - 1.6 degrees (paragraph 0145). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the taper of the distal end region to be 0.5 cm - 4.0 cm and the taper to have a taper angle relative to a center line of the distal end region that is 0.9 - 1.6 degrees, as taught by Wilson. This modification provides a tapered tip with dimensions that facilitate improved tracking through a tortuous and often diseased vasculature (Wilson, paragraph 0161). Regarding claims 14 and 15, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. However, the combined teaching fails to teach an outer diameter of the outer catheter approaches a size of an intracranial vessel, wherein the intracranial vessel is located between a cervical carotid to an M2 segment of a cerebral vessel. Wilson further teaches an outer diameter of an outer catheter (200) approaches a size of an intracranial vessel, wherein the intracranial vessel is located between a cervical carotid to an M2 segment of a cerebral vessel (paragraphs 0097, 0105, 0107, 0144). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify an outer diameter of the outer catheter to approach a size of an intracranial vessel, wherein the intracranial vessel is located between a cervical carotid to an M2 segment of a cerebral vessel, as taught by Wilson. This modification would provide a catheter system sized to navigate the carotid anatomy in order to treat various neurovascular pathologies at the level of the cerebral arteries, such as acute ischemic stroke (Wilson, paragraph 0065). Regarding claim 20, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. However, the combined teaching fails to explicitly teach the at least one radiopaque marker identifies a proximal end of the taper and the inner catheter further comprises a second radiopaque marker identifying a distal end of the inner catheter. Wilson further teaches (Figure 7C) a distal end region can have a first radiopaque marker (344a) and a second radiopaque marker (344b) can be located to indicate the border between the tapering of the distal tip (346) and the more proximal region of the inner catheter. This provides a user with information regarding an optimal extension of the distal tip (346) relative to the outer catheter (paragraph 0158). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the at least one radiopaque marker to identify a proximal end of the taper and the inner catheter to further comprise a second radiopaque marker identifying a distal end of the inner catheter, as taught by Wilson. This modification would provide a user with information regarding an optimal extension of the distal tip of the inner catheter relative to the outer catheter during a procedure (Wilson, paragraph 0158) and would provide a user with a visual indication that an entirety of the tapered tip crossed the blood vessel narrowing during the procedure. Regarding claim 22, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. However, the combined teaching fails to teach advancing the catheter system through the base sheath comprises advancing the catheter system without a guidewire. Wilson further teaches that the catheter system can be advanced together with a guidewire, over a guidewire pre-positioned, or without any guidewire at all (paragraphs 0150, 0167). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the catheter system such that advancing the catheter system through the base sheath comprises advancing the catheter system without a guidewire, as taught by Wilson. Wilson teaches that it was well known in the art before the effective filing date of the claimed invention to advance a catheter system without a guidewire to effectively reach a treatment location (Wilson, paragraphs 0150, 0167). This modification would reduce the number of steps in the procedure. Claims 10-13 are rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Jago (US 2020/0253579 A1) and Stenzel (US 2007/0010863 A1) as applied to claim 1 above, and further in view of Mas et al. (US 2009/0270808 A1) (“Mas”). Regarding claims 10 and 11, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. The combined teaching teaches that that blood vessel narrowing (52) is an atherosclerotic lesion. However, the combined teaching fails to explicitly teach prior to crossing the atherosclerotic lesion, positioning the distal end of the outer catheter proximal to the atherosclerotic lesion; withdrawing the inner catheter from the catheter lumen; and aspirating the atherosclerotic lesion through the catheter lumen, wherein withdrawing the inner catheter creates an internal vacuum within the distal end of the outer catheter and draws embolic material towards and/or through the distal end of the outer catheter. Mas teaches (Figures 10 and 11) aspiration catheters are used commonly in connection with interventional vascular procedures such as angioplasty, atherectomy, stent placement, and the like to aspirate debris that may result from an interventional procedure (paragraph 0002). Mas teaches positioning a distal end of an outer catheter (28) proximal to a clot/lesion/debris (48); withdrawing an inner catheter (74) from the catheter lumen; and aspirating the clot/lesion/debris through the catheter lumen, wherein withdrawing the inner catheter creates an internal vacuum within the distal end of the outer catheter and draws embolic material towards and/or through the distal end of the outer catheter (paragraph 0035). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the method taught by Fischell in view of Jago and Stenzel such that prior to crossing the atherosclerotic lesion, positioning the distal end of the outer catheter proximal to the atherosclerotic lesion; withdrawing the inner catheter from the catheter lumen; and aspirating the atherosclerotic lesion through the catheter lumen, wherein withdrawing the inner catheter creates an internal vacuum within the distal end of the outer catheter and draws embolic material towards and/or through the distal end of the outer catheter, as taught by Mas. This modification would aspirate debris and reduce the significant medical risk of migration downstream with blood flow. This modification would also remove thrombus that form on the luminal wall of the vessel that causes a clinically significant, even a total occlusion (Mas, paragraph 0002). Regarding claim 12, Fischell as modified by Jago, Stenzel, and Mas teaches (Fischell, Figures 23A-23F) the atherosclerotic lesion (52) is a partial occlusion or a complete occlusion. Regarding claim 13, Fischell as modified by Jago, Stenzel, and Mas teaches (Stenzel, Figures 11-13) probing the atherosclerotic lesion with the distal end region (20) of the inner catheter and finding a passage through the atherosclerotic lesion prior to crossing the atherosclerotic lesion and dilating the atherosclerotic lesion as the distal end region advances through the passage (Stenzel, paragraph 0063). Claims 17-19 are rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Jago (US 2020/0253579 A1) and Stenzel (US 2007/0010863 A1) as applied to claim 16 above, and further in view of Wilson et al. (US 2018/0193042 A1) (“Wilson”). Regarding claims 17-19, Fischell as modified by Jago and Stenzel teaches the invention substantially as claimed. However, the combined teaching fails to explicitly teach the maximum outer diameter approaches an inner diameter of the catheter lumen, wherein the maximum outer diameter is about 0.048" to about 0.080", and wherein the inner diameter of the catheter lumen is about 0.054" to about 0.088". Wilson teaches (Figures 2A and 2B) an inner catheter (300) that comprises a maximum outer diameter that is between about 0.048” to about 0.080” and a taper (346) of the distal end region tapers from the maximum outer diameter to a second outer diameter at a distal-most end. Wilson teaches that the maximum outer diameter approaches an inner diameter of the catheter lumen, wherein the inner diameter of the catheter lumen is about 0.054" to about 0.088" (paragraph 0148). This produces an appropriately sized gap between the inner catheter and the outer catheter while still maintaining a high degree of flexibility for navigating tortuous anatomy (paragraph 0147). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the maximum outer diameter to approach an inner diameter of the catheter lumen, wherein the maximum outer diameter is about 0.048" to about 0.080", and wherein the inner diameter of the catheter lumen is about 0.054" to about 0.088", as taught by Wilson. This modification would result in an appropriately sized gap between the inner catheter and the outer catheter while still maintaining a high degree of flexibility for navigating tortuous anatomy (Wilson, paragraph 0147). When the gap between the two components is too tight (e.g. less than about 0.003″), the force needed to slide the inner catheter relative to the outer catheter can result in damage to one or both of the components and increases risk to the patient during the procedure. The gap results in too tight of a fit to provide optimum relative sliding. When the gap between the two components is too loose (e.g. greater than about 0.010″), the distal end of the outer catheter forms a lip that is prone to catch on branching vessels during advancement through tortuous vasculature (Wilson, paragraph 0147). Claims 23, 24, and 27-30 are rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Chermoni (US 2002/0156496 A1), Jago (US 2020/0253579 A1), Stenzel (US 2007/0010863 A1), and Wilson et al. (US 2018/0193042 A1) (“Wilson”). Regarding claim 23 and 29, Fischell discloses (Figures 23A-23F) a method of treating a vasculature (45), the method comprising: inserting a catheter system through a base sheath (44) and towards an occlusion (52) in a vessel, the catheter system comprising: an outer catheter (142) having a catheter lumen; and an inner catheter (54) sized to insert through the catheter lumen, the inner catheter comprising a flexible, distal end region (118) with a taper (paragraphs 0037, 0125); advancing the taper of the inner catheter through the occlusion (52) in the vessel to dilate the proximal occlusion (Figures 23B and 23C; paragraphs 0205-0207); advancing the outer catheter (142) through the occlusion (52) that is dilated (Figure 23D; paragraph 0208); and withdrawing the inner catheter from the outer catheter (Figure 23E). Fischell fails to disclose that the occlusion is a proximal occlusion in a proximal vessel and the catheter system is inserted towards a distal occlusion in a distal vessel. Fischell fails to disclose treating the distal occlusion in the distal vessel. Fischell also fails to disclose that the proximal vessel is a common carotid artery, an external carotid artery, or an internal carotid artery. Fischell fails to disclose the inner catheter comprises a non-expandable, single-lumen inner catheter sized to insert through the catheter lumen, the inner catheter comprising a flexible, distal end region comprising a first section having a cylindrical wall and a second section having a taper, wherein the cylindrical wall has an outer diameter size-matched to the catheter lumen at the distal end of the outer catheter. Fischell fails to disclose the distal end region is substantially unreinforced and fully polymeric. In the same field of endeavor, Chermoni teaches that it is often necessary to treat multiple occlusions in a single procedure. For example, it may be necessary to insert a large diameter stent at one location, a small diameter stent at a second location and to perform a balloon angioplasty without a stent at a third location (paragraph 0003). Chermoni teaches (Figures 1-13) that a catheter system is inserted towards a distal occlusion, but first treats a first desired location, a first occlusion. After the first occlusion is treated, the catheter is navigated to the distal occlusion, and the distal occlusion is treated (paragraph 0044). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to first treat a proximal occlusion in a proximal vessel and then navigate the catheter system towards a distal occlusion in a distal vessel, and then treat the distal occlusion, as taught by Chermoni. This modification would allow multiple occlusions to be treated in the same procedure, without removing the catheter system from the body, which would cause much discomfort to the patient, prolong the duration of the procedure, and increase the chances of damaging a blood vessel (Chermoni, paragraph 0003). Jago teaches (Figure 2) that it is known in the art for a proximal occlusion (72) to be formed in a proximal vessel and a distal occlusion to form in a distal vessel (74). Jago teaches that the proximal vessel is a common carotid artery (10a) and the distal vessel is a distal carotid artery (10b). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the method taught by Fischell in view of Chermoni to first treat a proximal occlusion in a common carotid artery, as taught by Jago. This modification would treat a proximal occlusion that restricts flow of blood to the brain (Jago, paragraph 0013). In the same field of endeavor, Stenzel teaches (Figures 11-13) advancing a non-expandable, single-lumen catheter (NOTE: Figure 11 depicts a balloon. However, Stenzel teaches the device may include an inflation balloon) with a flexible (paragraphs 0033 and 0035), distal end region comprising a first section (30) having a cylindrical wall and a second section (20) having a taper over a guidewire (12) to a lesion (16). Stenzel teaches the guidewire (12) is positioned within the single lumen (38) of the inner catheter (Figure 11). Stenzel teaches the size and shape of the lesion (16) may block the vessel (14) to the extent that the guidewire is unable to cross the lesion (16). Stenzel teaches using the tapered end region of inner catheter (30) to cross an occlusion (16) in the artery (Figures 12 and 13). Stenzel teaches (Figures 12 and 13) that the tapered end region of the inner catheter pre-dilates the occlusion (16) in the artery (14) as the catheter system is advanced (Stenzel, paragraph 0061). Stenzel teaches that the distal tapered end region is substantially unreinforced and fully polymeric (paragraphs 0033 and 0035). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to substitute the inner catheter having a non-expandable, single-lumen and a substantially unreinforced and fully polymeric distal end region, taught by Stenzel, for the inner catheter taught by Fischell in view of Chermoni and Jago. Substitution of one known element (the pre-dilating catheter taught by Stenzel) for another element (the expandable pre-dilating inner catheter disclosed by Fischell) providing the same function to yield predictable results (pre-dilating occlusions to allow the catheter system to pass through occlusions where the size and shape of the occlusion may block the vessel) would have been obvious to one of ordinary skill in the art at the time of the invention. Wilson teaches (Figure 2B) an outer catheter (200) having a catheter lumen and a distal end. Wilson teaches an inner catheter sized to insert through the catheter lumen. Wilson teaches that the inner catheter has a flexible, distal end region comprising a first section having a cylindrical wall and a second section (346) having a taper. Wilson teaches that the cylindrical wall has an outer diameter size-matched to the catheter lumen at the distal end of the outer catheter. Wilson teaches that the second section (346) having a taper is configured to extend distal to the distal end of the outer catheter (200) such that the first region of the inner catheter having an outer diameter sized to match the inner diameter of the distal luminal portion (222) of the outer catheter (200) is positioned within the lumen of the outer catheter (200) such that it can minimize the lip at the distal end of the outer catheter (paragraph 0147). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the cylindrical wall to have an outer diameter size-matched to the catheter lumen at the distal end of the outer catheter, as taught by Wilson. This modification would minimize the lip at the distal end of the outer catheter (Wilson, paragraph 0147). Regarding claim 24, Fischell as modified by Chermoni, Jago, Stenzel, and Wilson teaches (Fischell, Figure 23F) deploying a stent (200) against the proximal occlusion (Fischell, paragraph 0211). Regarding claims 27 and 28, Fischell as modified by Chermoni, Jago, Stenzel, and Wilson above teach the invention substantially as claimed. However, the combined teaching fails to teach a first radiopaque marker that identifies a proximal end of the taper and a second radiopaque marker that identifies a distal end of the inner catheter. Wilson further teaches (Figure 7C) a distal end region of the inner catheter can have a first radiopaque marker (344a) and a second radiopaque marker (344b) can be located to indicate the border between the tapering of the distal tip (346) and the more proximal region of the inner catheter. This provides a user with information regarding an optimal extension of the distal tip (346) relative to the outer catheter (paragraph 0158). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the inner catheter taught by Fischell in view of Chermoni, Jago, Stenzel, and Wilson above to comprise a first radiopaque marker that identifies a proximal end of the taper and a second radiopaque marker that identifies a distal end of the catheter, as taught by Wilson. This modification would provide a user with information regarding an optimal extension of the distal tip of the inner catheter relative to the outer catheter during a procedure (Wilson, paragraph 0158) and would provide a user with a visual indication of when the entirety of the tapered tip is advanced through the occlusion during the procedure. Regarding claim 30, Fischell as modified by Chermoni, Jago, Stenzel, and Wilson teaches the taper of the distal end region is 0.5 cm - 4.0 cm (Fischell, paragraph 0064). Claim 25 is rejected under 35 U.S.C. 103 as being unpatentable over Fischell et al. (US 2019/0255299 A1) (“Fischell”) in view of Chermoni (US 2002/0156496 A1), Jago (US 2020/0253579 A1), Stenzel (US 2007/0010863 A1), and Wilson et al. (US 2018/0193042 A1) (“Wilson”) as applied to claim 23 above, and further in view of Zadno-Azizi et al. (US 2001/0049517 A1) (“Zadno-Azizi”). Regarding claim 25, Fischell as modified by Chermoni, Jago, Stenzel, and Wilson teaches the invention substantially as claimed. However, the combined teaching fails to teach that treating the distal occlusion comprises drawing aspiration through the outer catheter. In the same field of endeavor, Zadno-Azizi teaches (Figures 25 and 26) utilizing an outer catheter (406) for aspiration and irrigation of an occlusion (410’). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the method taught by Fischell in view of Chermoni, Jago, Stenzel, and Wilson such that treating the distal occlusion comprises drawing aspiration through the outer catheter, as taught by Zadno-Azizi. This modification would allow blood containing emboli or other particles to be aspirated away and removed from the patient to reduce the risk of embolization and stroke caused by particles and other debris moving downstream to the brain (Zadno-Azizi, paragraphs 0010 and 0135). Response to Arguments Applicant's arguments filed 9/23/26 regarding the rejection of claim 1 under 35 U.S.C. § 103 have been fully considered but they are not persuasive. Regarding claim 1, the Applicant has argued that the Stenzel reference uses the word "may" to introduce features of the device. The Applicant argues that a separate inflation lumen is necessary to inflate a balloon of a balloon catheter. The Examiner disagrees with the Applicant's interpretation of the Stenzel reference. Stenzel teaches multiple embodiments that do not comprise a balloon. For example, Figures 12 and 13 show a pre-dilation device crossing a lesion without a balloon. In paragraph 0058, Stenzel teaches an over-the-wire configuration, instead of the rapid exchange configuration depicted in the other embodiments. In paragraph 0001, Stenzel teaches that both "over-the-wire and rapid-exchange type catheters are known." The Applicant has argued that Stenzel recognized that a separate inflation lumen is necessary to inflate a balloon of a balloon catheter. The Examiner is not disputing that. The Examiner's position is that a balloon and/or stent delivery system are simply additional features that any of the embodiments can have. The use of "may" means that they are not necessary for crossing a lesion. As explained in the previous Office Action, although the balloon is depicted in Figure 11, Stenzel teaches pre-dilation devices without a balloon. Paragraph 0059 teaches that the "predilation device 10 may further include an inflation balloon and/or stent delivery system." A balloon and/or stent delivery system are additional features that one having ordinary skill in the art would recognize are not necessary for crossing an occlusion. The Applicant has also argued that substituting the predilation device of Stenzel would destroy Fischell's inventive purpose. The Examiner disagrees. The inventive purpose is to pre-dilate a lesion. Both the device of Fischell and the device of Stenzel do that. The Applicant has further argued that the Fischell balloon delivery system is designed specifically to track over a guidewire whereas Stenzel has a guidewire that runs outside the catheter and thus can be solid as shown in FIG. 4. The Examiner did not cite Figure 4 of Stenzel. The rejection cites Figure 11, which Stenzel teaches is an over-the-wire configuration. The Applicant has further argued that Stenzel describes a catheter that has a distal tip that is essentially a drill bit that can be rotated to "grind" through an occlusion and that substitution of a rigid, torqueable grinding device like in Stenzel, for a "soft" inflatable balloon catheter like in Fischell would not yield predictable results. The Examiner disagrees. Paragraph 0033 of Stenzel teaches that shaft portion 30 may be made of any suitable material, such as catheter materials including, but not limited to, moldable polymers, polyether block amide (PEBA), nylon or polyethyleneterephthalate (PET), polyurethane, latex, silicone rubber, natural rubber, polyvinyl chloride, polyamide, polyamide elastomer, copolymer of ethylene and vinyl acetate, polyethylene, polyimide, stainless steel and suitable alloy materials such as nickel-titanium alloys, cobalt-chromium-nickel alloys, etc. Paragraph 0035 of Stenzel teaches that the tip 20 may comprise the same material as the shaft 30. Many of these materials are flexible, as claimed. And as explained above, the substitution would yield predictable results, as both devices are used to pre-dilate lesions. For these reasons, the Examiner maintains that claim 1 as amended does not distinguish over the prior art of record. Applicant’s arguments with respect to claims 23-25 and 27-30 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTIAN D KNAUSS whose telephone number is (571)272-8641. The examiner can normally be reached M-F 12:30-8:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 571-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.D.K/Examiner, Art Unit 3771 /DARWIN P EREZO/Supervisory Patent Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Feb 17, 2026
Application Filed
Apr 21, 2026
Response after Non-Final Action
Jun 24, 2026
Non-Final Rejection mailed — §103
Sep 23, 2026
Response Filed
Nov 12, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788843
METHODS AND COLLAGEN PRODUCTS FOR TISSUE REPAIR
7y 2m to grant Granted Nov 10, 2026
Patent 12778803
CORNEAL MARKER TOOLS FOR OPHTHALMIC PROCEDURES
4y 11m to grant Granted Nov 03, 2026
Patent 12778609
ASPIRATION PULSATOR
2y 8m to grant Granted Nov 03, 2026
Patent 12778574
SINGLE-ANCHOR MECHANISM AND SUTURING DEVICE
2y 2m to grant Granted Nov 03, 2026
Patent 12773195
TISSUE PLUG
5y 4m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+32.7%)
3y 3m (~2y 6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 430 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month